Chronic spontaneous urticaria (CSU)

Active Ingredient: Remibrutinib

Indication for Remibrutinib

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Remibrutinib is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.

For this indication, competent medicine agencies globally authorize below treatments:

25 mg twice daily

For:

Dosage regimens

Oral, 25 milligrams remibrutinib, 2 times daily.

Detailed description

The recommended dose of remibrutinib is 25 mg taken orally twice daily, once in the morning and once in the evening.

If a patient misses one or more doses of remibrutinib, the patient should be instructed to take the next dose at its regularly scheduled time. Extra doses of remibrutinib should not be taken to make up for the missed dose or doses.

Prescribers are advised to periodically reassess the need for continued therapy. Consideration should be given to discontinuing treatment in patients who have shown no response after 24 weeks of treatment for CSU.

Dose interruption

It is recommended to interrupt remibrutinib for 3 to 7 days before surgery and for 3 to 7 days after surgery depending upon the type of surgery and the risk of bleeding.

Elderly

No specific dose adjustment is required for elderly patients (aged ≥65 years). Limited data are available on the use of remibrutinib in patients older than 65 years.

Active ingredient

Remibrutinib

Remibrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor that forms a covalent bond with a cysteine residue in the BTK active site, leading to durable inactivation of BTK. The therapeutic effect of remibrutinib in CSU is achieved through inhibition of mast cell and basophil degranulation, including release of histamine and other proinflammatory mediators, mediated by pathogenic IgE or IgG directed against the FcεR1 or IgE.

Read more about Remibrutinib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.